Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease
Trends in Immunology · 2026-11 · 47 (11) · 979-995
DOI: 10.1016/j.it.2026.06.001 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Trends in Immunology, 2026-11. Verfasst von Qing Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, F-75012 Paris, France; Gut, Liver & Microbiome Research (GLIMME…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Gastrointestinal Microbiome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: MSDAVENIR, Takeda Pharmaceutical Company, European Research Council.
Abstract (Originalsprache)
Growing evidence indicates that gut microbiota-derived metabolites are key regulators of immunometabolism in inflammatory bowel disease (IBD). Intestinal epithelial cells and immune cells exhibit profound metabolic alterations in IBD. Microbial metabolites act as intermediates in host-microbe communication, reshaping mitochondrial functions and cellular metabolic pathways, thereby impacting immune functions. Dysbiosis may, therefore, perturb immune homeostasis by rewiring host metabolic circuits. Understanding how microbial metabolites orchestrate immunometabolic crosstalk in the gut and leveraging it to recalibrate host immunometabolic circuits represents promising, underexplored therapeutic avenues. In this review, we highlight emerging concepts on how gut microbiota-derived metabolites shape immune cell immunometabolism and discuss the therapeutic potential of targeting the microbiota-metabolite-immunometabolism axis in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, F-75012 Paris, France; Gut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France.
- Sorbonne Université, INSERM UMRS-938, Centre de Recherche Saint-Antoine, CRSA, AP-HP, F-75012 Paris, France; Gut, Liver & Microbiome Research (GLIMMER) FHU, Paris, France; Université Paris-Saclay, INRAE, AgroParisTech,…
Förderung
- MSDAVENIR
- Takeda Pharmaceutical Company
- European Research Council
Zitieren
APA
Li, Q., de Oliveira Formiga, R., & Sokol, H. (2026). Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease. Trends in Immunology, 47(11), 979-995. https://doi.org/10.1016/j.it.2026.06.001
Vancouver
Li Q, de Oliveira Formiga R, Sokol H. Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease. Trends in Immunology. 2026;47(11):979-995. doi:10.1016/j.it.2026.06.001
BibTeX
@article{Li2026,
author = {Li, Qing and de Oliveira Formiga, Rodrigo and Sokol, Harry},
title = {Gut microbiome metabolites meet immunometabolism in inflammatory bowel disease},
journal = {Trends in Immunology},
year = {2026},
volume = {47},
number = {11},
pages = {979--995},
doi = {10.1016/j.it.2026.06.001}
}
EUVIMED